Thrombotic risk factors in Chinese nonmalignant and noncirrhotic patients with portal vein thrombosis

Qi, Xingshun; Wu, Feifei; He, Chuangye; Fan, Daiming; Han, Guohong

doi:10.1097/meg.0000000000000221

Cited by 10 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study showed that MTHFR C677T polymorphism didn’t constitute a significant risk factor for PVT in either heterozygote or homozygote states and therefore it was in agreement with the results of Vayá et al [ 14 ] and Mangia et al [ 18 ] that demonstrated no significant association between MTHFR C677T polymorphism and PVT. However, our study was inconsistent with the results of other studies reporting positive correlation between this MTHFR variant and PVT [ 13 , 15 , 19 – 21 ]. The reason for the inconsistency between the various studies remains to be determined.…”

Section: Discussioncontrasting

confidence: 99%

Role of Hyperhomocysteinemia and Methylene Tetrahydrofolate Reductase C677T Polymorphism in Idiopathic Portal Vein Thrombosis

Ghaznavi

Soheili

Samiei

et al. 2016

VSI

View full text Add to dashboard Cite

Purpose:Portal vein thrombosis (PVT) is a rare and life-threatening vascular disorder characterized by obstruction or narrowing of the portal vein. Hyperhomocysteinemia and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism has been studied in PVT patients with conflicting results. In the present study the association of hyperhomocysteinemia and MTHFR C677T polymorphism with PVT risk was investigated in Iranians.Materials and Methods:Our study population consisted of 10 idiopathic PVT patients and 80 healthy control subjects matched for age and sex. MTHFR C677T polymorphism was genotyped by the polymerase chain reaction technique combined with restriction enzyme fragment length polymorphism (PCR-RFLP) technique and plasma total homocysteine (tHcy) levels were determined by enzyme immunoassay method.Results:Mean plasma tHcy levels were significantly higher in PVT patients (20.2±6.8) than control subjects (10.9±4.7) (P=0.001). Moreover, plasma tHcy levels were significantly higher in 677T allele carriers relative to 677C allele carriers in both PVT patients (P=0.01) and control subjects (P=0.03). Neither homozygote nor heterozygote genotypes of MTHFR C677T polymorphism correlated significantly with PVT risk (P>0.05). Moreover, MTHFR C677T polymorphism didn’t increase the risk of PVT under dominant (CT+TT vs. CC) or recessive (TT vs. CC+CT) genetic models analyzed (P>0.05). The difference in frequency of minor 677T allele between PVT patients and control subjects was not statistically significant (P>0.05).Conclusion:Based on the current study, we suggest that hyperhomocysteinemia constitutes a significant and common risk factor for PVT. Also, MTHFR C677T polymorphism is not a risk factor for PVT but is a contributing factor for elevated plasma tHcy levels.

show abstract

Section: Discussioncontrasting

confidence: 99%

Role of Hyperhomocysteinemia and Methylene Tetrahydrofolate Reductase C677T Polymorphism in Idiopathic Portal Vein Thrombosis

Ghaznavi

Soheili

Samiei

et al. 2016

VSI

View full text Add to dashboard Cite

show abstract

“…By comparison, the prevalence of the JAK2 V617F mutation in Chinese patients with EHPVO was comparable to the Western data (42,47).…”

Section: Jak2 V617f Mutationsupporting

confidence: 64%

Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment

Stefano

Qi²,

Betti³

et al. 2016

Thromb Haemost

Self Cite

View full text Add to dashboard Cite

SummarySplanchnic vein thrombosis (SVT) encompasses Budd-Chiari syndrome (BCS), extrahepatic portal vein obstruction (EHPVO), and mesenteric vein thrombosis. Philadelphia-negative myeloproliferative neoplasms (MPNS) are the leading systemic cause of non-cirrhotic and non-malignant SVT and are diagnosed in 40 % of BCS patients and one-third of EHPVO patients. In SVT patients the molecular marker JAK2 V617F is detectable up to 87 % of those with overt MPN and up to 26 % of those without. In the latter, other MPN molecular markers, such as mutations in JAK2 exon 12, CALR and MPL genes, are extremely rare. Immediate anticoagulation with heparin is used to treat acute patients. Upon clinical deterioration, catheter-directed thrombolysis or a transjugular intrahepatic portosystemic shunt is used in conjunction with anticoagulation. Orthotopic liver transplantation is the only reliable option in BCS patients with a lack of a response to other treatments, without contraindication due to MPN. Long-term oral anticoagulation with vitamin K-antagonists (VKA) is recommended in all SVT patients with the MPN-related permanent prothrombotic state; the benefits of adding aspirin to VKA are uncertain. Cytoreduction is warranted in all SVT patients with an overt MPN, but its appropriateness is doubtful in those with molecular MPN without hypercythaemia.

show abstract

“…On the other hand, Western studies have also suggested that routine screening for PNH should be considered in PVT patients (19). However, there was a very low prevalence of PNH in Chinese patients with PVT (19,20), which did not support the necessity of routine screening for PNH in such patients.…”

mentioning

confidence: 95%

Portal vein thrombosis as the first presentation of paroxysmal nocturnal hemoglobinuria

Wang

Guo

Tang

et al. 2022

DD&T

Self Cite

View full text Add to dashboard Cite

paroxysmal nocturnal hemoglobinuria, portal vein thrombosis, anticoagulation therapy Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired clonal hematopoietic stem cell disorder, characterized by hemolytic anemia, bone marrow failure and thrombosis. Portal vein thrombosis (PVT) is relatively rare in patients with PNH. In this paper, we reported PVT as the first clinical presentation of PNH in a female patient. PVT related symptoms resolved after anticoagulation therapy.

show abstract

Thrombotic risk factors in Chinese nonmalignant and noncirrhotic patients with portal vein thrombosis

Cited by 10 publications

References 29 publications

Role of Hyperhomocysteinemia and Methylene Tetrahydrofolate Reductase C677T Polymorphism in Idiopathic Portal Vein Thrombosis

Role of Hyperhomocysteinemia and Methylene Tetrahydrofolate Reductase C677T Polymorphism in Idiopathic Portal Vein Thrombosis

Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment

Portal vein thrombosis as the first presentation of paroxysmal nocturnal hemoglobinuria

Contact Info

Product

Resources

About